UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
NYMOX PHARMACEUTICAL CORP.
.......................................................
(Name of Issuer)
COMMON SHARES
.......................................................
(Title of Class of Securities)
67076P102
.......................................................
(CUSIP Number)
11/26/03
.......................................................
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No. 67076P102
.......................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Generic Trading of Philadelphia, LLC/IRS #133963802
........................................................................
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ...................................................................
(b) ...................................................................
3. SEC Use Only ......................................................
4. Citizenship or Place of Organization Delaware
........................................................................
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power 1,012,394
.....................................................................
6. Shared Voting Power
.....................................................................
7. Sole Dispositive Power
.....................................................................
8. Shared Dispositive Power
.....................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
.....................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
.....................................................................
11. Percent of Class Represented by Amount in Row (9)
12. Type of Reporting Person (See Instructions)
.....................................................................
BD
.....................................................................
.....................................................................
.....................................................................
.....................................................................
.....................................................................
Item 1.
(a) Name of Issuer
Nymox Pharmaceutical Corp.
(b) Address of Issuer's Principal Executive Offices
9900 CAVENDISH BOULEVARD SUITE 306,
SAINT LAURENT H4M 2V2 CANADA FF
Item 2.
(a) Name of Person Filing
Generic Trading of Philadelphia, LLC
(b) Address of Principal Business Office or, if none, Residence
1270 Ave. of the Americas, NY, NY 10020
(c) Citizenship
U.S.
(d) Title of Class of Securities
Common
(e) CUSIP Number
67076P102
Item 3. If this statement is filed pursuant to Sect. 240.13d-1(b) or
240.13d-2(b)or (c), check whether the person filing is a:
(a) [X] Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act
(15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19)
of the Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of
the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with
Sect.240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance
with Sect. 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with Sect. 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Sect. 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in
Item 1.
(a) Amount beneficially owned: 1,012,394.
(b) Percent of class: 4.7%.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 1,012,394.
(ii) Shared power to vote or to direct the vote ...
(iii) Sole power to dispose or to direct the disposition of ...
(iv) Shared power to dispose or to direct the disposition of ...
Instruction. For computations regarding securities which represent a right to
acquire an underlying security see Sect. 240.13d3(d)(1).
Item 5. Ownership of Five Percent or Less of a Class
This statement is being filed to report that as of February 8, 2001
Generic Trading of Philadelphia, LLC has ceased to be the beneficial
owner of more than 5% of the class of securities.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
01/14/2004
..........................
Date
Ron Shear
..........................
Signature
Ron Shear/President
..........................
Name/Title